Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: A novel 5-lipoxygenase inhibitor

Inflammation Research

Volumn 57, Issue 3, 2008, Pages 135-143

  Shirumalla, R K ^a   Sharma, P ^a   Dastidar, S G ^a   Paliwal, J K ^a   Kakar, S ^a   Varshney, B ^a   Singh Saini, G ^a   Sattigeri, V ^a   Salman, M ^a   Ray, A ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

5 Lipoxygenase; Airway reactivity; CYP inhibition; Pharmacokinetics; RBx 7796

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOCHROME P450; DEXAMETHASONE; LEUKOTRIENE B4; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MONTELUKAST; RBX 7796; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; ENZYME INHIBITION; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; RAT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BRONCHIAL HYPERREACTIVITY; CALCIMYCIN; DOGS; HUMANS; HYDROXYUREA; IONOPHORES; LEUKOTRIENE B4; LIPOPOLYSACCHARIDES; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED BALB C; NEUTROPHILS; RATS; RATS, WISTAR; SALTS;

EID: 41449117235     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-7149-4     Document Type: Article

References (34)

1. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998; 157: S210-13.
2. Holgate ST, Sampson AP Antileukotriene therapy. Future directions. Am J Respir Crit Care Med 2000; 161: S147-53.
3. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J et al. Pharmacology of Montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995; 73: 191-201.
4. Aharony D. Pharmacology of leukotriene receptor antagonists. Am J Respir Crit Care Med 1998; 157(6 Pt 1): S214-9.
5. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
6. Garcia-Marcos L, Schuster A, Pérez-Yarza EG. Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf 2003; 26: 483-518.
7. Evans DJ, Barnes PJ, Spaethe SM, Van Alstyne EL, Mitchell MI, O'connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 51: 1178-84.
8. Showell HJ, Conklyn MJ, Alpert R, Hingorani GP, Wright KF, Smith MA et al. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J Pharmacol Exp Ther 1998; 285: 946-54.
9. Kilfeather S. 5-lipoxygenase inhibitors for the treatment of COPD. Chest 2002; 121: 197S-200S.
10. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997; 17: 22S-30S.
11. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC et al. The effect of inhibition of 5-lipoxygenase by Zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059-66.
12. Brooks CD, Summers JB. Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 1996; 39: 2629-54.
13. Nasser SM, Bell GS, Foster S, Spruce KE, Macmillan R et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49: 749-56.
14. Nasser SM, Bell GS, Hawksworth RJ, Spruce KE, Macmillan R, Williams, AJ et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994a; 49: 743-8.
15. Werz O, Szellas D, Henseler M, Steinhilber D. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 1998; 54: 445-51.
16. Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 2004; 142: 861-8.
17. Werz O, Steinhilber D. Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds. Exp Op Ther Pat 2005; 15: 505-19.
18. Werz O, Steinhilber D. Development of 5-lipoxygenase inhibitors-lessons from cellular enzyme regulation. Biochem Pharmacol 2005a; 70: 327-33.
19. Shirumalla RK, Naruganahalli KS, Dastidar SG, Sattigeri V, Kaur G, Deb C et al. RBx 7796: A novel inhibitor of 5-lipoxygenase. Inflamm Res 2006; 55: 517-27.
20. Hatzelmann A, Ullrich V. Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes. Eur J Biochem 1987; 169: 175-84.
21. Cieslewicz G, Tomkinson A, Adler A, Duez C, Schwarze J, Takeda K et al. The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J Clin Invest 1999; 104: 301-8.
22. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156: 766-75.
23. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW et al. The role of IL-13 in established allergic airway disease. J Immunol 2002; 169: 6482-9.
24. Wegner CD, Gundel RH, Abraham WM, Schulman ES, Kontny MJ, Lazer ES et al. The role of 5-lipoxygenase products in preclinical models of asthma. J Allergy Clin Immunol 1993; 91: 917-29.
25. Henderson WR, Chi EY, Maliszewski CR Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol 2000; 164: 1086-95.
26. Choi IW, Sun-Kim, Kim YS, Ko HM, Im SY, Kim JH et al. TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation. J Allergy Clin Immunol 2005, 116: 537-43.
27. Kim DC, Hsu FI, Barrett NA, Friend DS, Grenningloh R, Ho IC et al. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol 2006; 176: 4440-8.
28. Taube C, Miyahara N, Ott V, Swanson B, Takeda K, Loader J et al. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006; 176: 3157-64.
29. Henderson WR, Lewis DB, Albert RK, Zhang Y, Lamm WJ, Chiang GK et al. The importance of leukotrienes in airway inflammation in a mouse model of asthma. J Exp Med 1996; 184: 1483-94.
30. Turner CR, Lackey MN, Quinlan MF, Griswold DE, Schwartz LW, Wheeldon EB. Therapeutic intervention in a rat model of adult respiratory distress syndrome: II. Lipoxygenase pathway inhibition. Circ Shock 1991; 34: 263-9.
31. Kips JC, Tavernier J, Pauwels RA. Tumor necrosis factor causes bronchial hyperresponsiveness in rats. Am Rev Respir Dis 1992; 145: 332-6.
32. Uno T, Tanaka H, Nakai N, Nagai H. Participation of leukotriene D4 and tumor necrosis factor on lipopolysaccharide-induced airway hyperresponsiveness in guinea pigs. Biol Pharm Bull 1997; 20: 332-7.
33. Lefort J, Motreff L, Vargaftig BB. Airway administration of Escherichia coli endotoxin to mice induces glucocorticosteroid-resistant bronchoconstriction and vasopermeation. Am J Respir Cell Mol Biol 2001; 24 : 345-51.
34. Bell RL, Harris RR, Malo PE, Bouska JB, Shaughnessy TK, Hulkower KI et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther 1997; 280: 1366-73.